Kaitlyn D’Onofrio

DocwireNews

Continuous use of nonsteroidal anti&#8208;inflammatory drugs (<a href="https://www.docwirenews.com/docwire-pick/nsaid-use-and-risk-of-kidney-disease-in-active-adults/">NSAIDs</a>) in patients with <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/anti-tnf-withdrawal-ankylosing-spondylitis/">ankylosing spondylitis</a> (AS) may result in <a href="https://www.docwirenews.com/conference-coverage/soho/hypertension-bosutinib-imatinib/">hypertension</a>, a new study suggests.&ldquo;Cardiovascular disease (CVD) is the leading cause of death in many parts of the developed world, and the evidence for increased CVD burden and cardiovascular (CV) risk in patients with inflammatory rheumatic diseases is well recognized. Multiple population-based studies have demonstrated increased CV events and CV-related mortality in Ankylosing Spondylitis (AS),&rdquo; wrote the researchers, adding, &ldquo;The effect of NSAID use on CV risk factors such as hypertension among individuals with AS remains unclear.&rdquo; The study&rsquo;s findings were published in <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.24070">Arthritis Care &amp; Research</a>.Adult AS patients included in the study underwent evaluation every four to six months. Patients filled out questionnaires pertaining to disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]) and functional impairment (Bath Ankylosing Spondylitis Functional Index). Six-month medication history was self-reported; for <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/study-find-nsaids-improve-survival-in-head-and-neck-cancer/">NSAID </a>and TNF inhibitor (TNFi) users, this included dosage, frequency, and duration, as well as missed doses and whether the patient was still taking the medication. Visits also included an evaluation of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels. Beginning in 2013, each visit also included assessment of blood pressure and body mass index (BMI).<h2>NSAIDs Increase Hypertension Risk</h2>Final analysis included 628 AS patients (72% were male) without baseline <a href="https://www.docwirenews.com/docwire-pick/what-is-hypertension/">hypertension</a>. All patients had at least one year of follow-up. Mean age at baseline was 39 years. A total of 200 patients reported continuous <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/trial-comparing-tanezumab-nsaids-oa/">NSAID</a> use, while 428 reported low-dose or no NSAID use. There were no significant between-group differences regarding demographics, but the continuous NSAID cohort had significantly higher disease activity per the BASDAI (P = 0.03) and ASDAS (P = 0.04), and more continuous NSAID patients had an elevated CRP (P = 0.03). The no- or low-dose NSAID group had a higher use rate of biologics compared to the continuous NSAID group (47% vs. 33%, P &lt; 0.001).During a median seven years of follow-up, 129 patients received a new hypertension diagnosis. Of the hypertension patients, 40% were on continuous NSAIDs, 47% were on TNFi, and 16% were on both.&ldquo;After adjustment for study site, age, sex, race, BMI, TNFi use, and disease activity by ASDAS, continuous NSAID use was associated with an increased risk of incident hypertension, compared with non-continuous or no NSAID use (HR 1.12, 95%CI 1.04-1.20),&rdquo; the researchers observed. Using this same model, other predictors of hypertension were baseline age (HR 1.07 per year, 95%CI 1.06-1.09) and obese BMI (HR 3.24, 95% CI 1.86-5.63). &ldquo;The association did not differ in subgroups defined by age (p=0.93), BMI (p=0.60), disease activity (p=0.23), or TNFi use (p=0.89),&rdquo; the authors added.The researchers concluded by calling for future studies to &ldquo;focus on precision medicine and predicting risk and benefit for patients in whom continuous NSAIDs are being considered.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

NSAIDs May Increase Hypertension Risk in Ankylosing Spondylitis

Hypertension

Continuous use of nonsteroidal anti‐inflammatory drugs (NSAIDs) in patients with ankylosing spondylitis (AS) may result in hypertension, a new study suggests.
 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe